MENINGOCOCCAL A+C+W135 VACCINE

Select language:
Permalink

 

Indications

  • Prevention of meningitis due to meningococci groups A, C and W135:
    • in mass immunisation campaigns in the event of an outbreak due to meningococcus A, C or W135
    • in travellers spending more than 1 month in hyperendemic areas

Composition, forms, route of administration

  • Inactivated bacterial vaccine, polysaccharide
  • Powder for injection in multidose vial, to be dissolved with the entire vial of the diluent supplied by the manufacturer, for SC injection only

Dosage and vaccination schedule

  • Child from 2 years and adult: 0.5 ml single dose

Contra-indications, adverse effects, precautions

  • Do not administer to patients with history of an allergic reaction to a previous injection of meningococcal vaccine.
  • Vaccination should be postponed in the event of severe acute febrile illness; minor infections are not contra-indications.
  • May cause: mild local reaction, mild fever.
  • Do not mix with other vaccines in the same syringe (inactivation of vaccines).
  • If administered simultaneously with EPI vaccines, use different syringes and injection sites.
  • Pregnancy: no contra-indication
  • Breast-feeding: no contra-indication

Remarks

  • Immunity develops 7 to 10 days after injection, and lasts for approximately 3 years.

Storage

 
 
  • Powder: between 2 °C and 8 °C.
  • Diluent: a cold chain is not required for storage. However, at least 12 hours before reconstitution of the vaccine, the diluent must be refrigerated between 2 °C and 8 °C so that the diluent and lyophilised powder are at the same temperature: a temperature difference during reconstitution may reduce vaccine efficacy. Do not freeze.
  • Reconstituted vaccine: between 2 °C and 8 °C, for 6 hours maximum.